ENTR-601-44 - matching placebo

Preclinical

ENTR-601-44 - matching placebo is one of 6 therapeutic programs targeting Duchenne Muscular Dystrophy (DMD). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Duchenne Muscular Dystrophy (DMD)Recruiting

Duchenne Muscular Dystrophy (DMD)Preclinical

Recruiting

Competition

Competitive Landscape

7 competitors in Duchenne Muscular Dystrophy (DMD)

#DrugCompanyPhaseTrials

SGLT2 Inhibitor

Eli Lilly

Phase 1

1 2

Bmn 351

BioMarin Pharmaceutical

Phase 2

1 3

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Phase 1

1 4

ENTR-601-45

EEntrada Therapeutics, Inc.

Phase 2

2 5

ENTR-601-44

EEntrada Therapeutics, Inc.

Phase 2

2 6

ENTR-601-44 - matching placebo

EEntrada Therapeutics, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

PreclinicalRecruiting

Duchenne Muscular Dystrophy (DMD)

NCT07037862

Clinical

Trials by Indication[1]

Duchenne Muscular Dystrophy (DMD)1 trial

A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping With an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-44, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-44 (ELEVATE-44)

Recruiting·EEntrada Therapeutics, Inc.·Preclinical·NCT07037862·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ENTR-601-44 - matching placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for ENTR-601-44 - matching placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Entrada Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: EEntrada Therapeutics, Inc.

ENTR-601-44 - matching placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Duchenne Muscular Dystrophy (DMD)1 trial

References

Drug Info

Quick Facts

Related News